



Primary IR Contact

Investor Relations and Public Affairs

Phone: 650 837 8194

Fax: 650 837 8205

E-mail: shubbard@exelixis.com

Corporate Profile

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally. We are steadfast in our commitment to prudently reinvest in our business to maximize the potential of our pipeline. We intend to supplement our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis recently earned a spot on Deloitte's Technology Fast 500 list, a yearly award program honoring the 500 fastest-growing companies over the past four years.

Recent Headlines

03/15/18

Exelixis Submits U.S. Supplemental New Drug Application for CABOMETYX® (Cabozantinib) for Previously Treated Advanced Hepatocellular Carcinoma

03/06/18

Exelixis Announces Webcasts of Investor Conference Presentations in March

02/26/18

Exelixis Announces Collaborator Daiichi Sankyo's Submission of Regulatory Filing for Esaxerenone (CS-3150) in Japan

Upcoming Events

Date	Title
March 27, 2018 11:00 a.m. ET	Exelixis, Inc. at Needham Healthcare Conference

Stock Performance

EXEL (Common Stock)

Exchange NASDAQ (US Dollar)

Price \$24.13

Change (%) ▼ 0.38 (1.55%)

Volume 1,713,856

52 Week Low \$18.03

Market Cap \$7,262,491,384

Rolling EPS 0.49

PE Ratio 49.6586

Shares Outstanding 296,307,278

Data as of 03/21/18 4:00 p.m. ET



Analyst Estimates / Ratings

Mean Recommendation: 2.1



Sell

Strong Buy

Unable to fulfill request.

SEC Filings

Filing Date	Form	Description	Filing Group
03/07/18	4	Statement of changes in beneficial ownership of securities	3,4,5
03/07/18	4	Statement of changes in beneficial ownership of securities	3,4,5
03/07/18	4	Statement of changes in beneficial ownership of securities	3,4,5

Corporate Governance

Michael Morrissey, Ph.D.	President and Chief Executive Officer
Gisela M. Schwab, MD	President, Product Development and Medical Affairs and Chief Medical Officer
Christopher J. Senner	Executive Vice President and Chief Financial Officer
Dana Aftab Ph.D.	Executive Vice President, Business Operations
Laura Dillard	Senior Vice President, Human Resources
P.J. Haley, MBA	Senior Vice President, Commercial
Jeffrey J. Hessekiel, J.D.	Executive Vice President and General Counsel
Susan Hubbard	Executive Vice President, Public Affairs and Investor Relations
Peter Lamb, Ph.D.	Executive Vice President, Scientific Strategy and Chief Scientific Officer

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	428	7,570.32	85.5	253,279,460
Mutual Fund	502	3,788.20	44.2	131,036,892
Insider *	15	109.22	1.6	4,708,758

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
Fidelity Management & Research Company	36,007,692	12.2	-4,669,337	12/31/17
The Vanguard Group, Inc.	26,351,871	8.9	564,910	12/31/17
Meditor Capital Management Limited	16,484,638	5.6	-932,100	12/31/17
BlackRock Institutional Trust Company, N.A.	15,410,188	5.2	-195,557	12/31/17
Goldman Sachs & Company, Inc.	10,176,532	3.4	411,733	12/31/17
Matrix Capital Management Company, LLC	10,000,000	3.4	-5,117,460	12/31/17
T. Rowe Price Associates, Inc.	8,979,035	3.0	-335,917	12/31/17
AQR Capital Management, LLC	7,325,932	2.5	1,307,991	12/31/17

Data provided by Nasdaq. Minimum 15 minutes delayed.